Carry The Breast Cancer Tumor Lysis Protein Nanoparticles To Build Their In Vitro Anti-tumor Immune Effect Of The Preliminary Assessment

Objective To prepare two nanocarrier systems of nanoparticles(NPs) linked with proteins or nanoparticles encapsulating proteins for delivering tumor lysate protein with the biodegradable and biocompatible material poly (D, L-lactide co-glycolide) copolymer (PLGA), choosing the better nanocarrier and to evaluate the nanocarrier's immunogenicity for triggering anticancer immune reaction with in vitro cytotoxicity assay. Methods The sonication emulsification/solvent evaporation method was employed for preparation of nanoparticles for linking proteins. And nanoparticles linked with proteins was done by condensation reaction of Amino group and carboxyl group. The linking efficiency was improved by optimizing the condensation reaction. The double emulsion method was employed for preparation of nanoparticles encapsulating proteins. The morphology, size, zeta potential, and encapsulation efficiency of the NP were assayed and optimized. Next, contrasting the linking nanocarrier and the encapsulating nanocarrier with its delivering efficiency of proteins. And Then the choosed nanocarrier was utilized to simulate the peripheral blood mononuclear cells (PBMC). The cytotoxicity of PBMC against the MCF7 cancer cells was evaluated using a standard MTS assay. Results The choosed protein delivery system was the encapsulating nanocarrier. The obtained NPs were negatively charged, spherical in shape, relatively uniform in size, with a mean diameter about 80nm and a protein encapsulation rate around 80%.The NP-stimulated PMBC generated a significantly higher anticancer cytotoxicity in vitro compared to the control groups (P<0.05). Conclusion The NPs prepared from the encapsulating nanocarrier are of good physicochemical properties and can encapsulate protein antigen with high efficiency. Moreover, the NPs significantly enhanced the immunogenicity of the MCF7 tumor lysate protein, suggesting that nanotechnology may have potential applications in immunotherapy against breast cancer.